All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke with Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK. We asked, How might the MORPHO trial of gilteritinib impact clinical practice?
How might the MORPHO trial of gilteritinib impact clinical practice?
Firstly, Craddock provides an overview of the phase III MORPHO trial (NCT02997202), highlighting the impact of measurable residual disease status pre- or posttransplant on survival outcomes; then, he considers the implications on future trials assessing posttransplant maintenance therapies in other patient subgroups. Craddock concludes by emphasizing the need for more randomized trials to optimize transplant outcomes.
This interview can also be accessed as a podcast here.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox